18889881171
Kalkine 0
countryflagUS

Accolade Inc

Healthcare US ACCD

NoneUSD
-(-%)

Last update at 2025-05-08T13:17:35.094569Z

Day Range

--
LowHigh

52 Week Range

3.0815.36
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap291.54M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-53.61900M
  • Revenue TTM441.03M
  • Revenue Per Share TTM5.71
  • Gross Profit TTM 165.26M
  • Diluted EPS TTM-1.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Income before tax -463.27400M -128.76300M -50.64800M -51.23600M -56.44100M
Minority interest - - - - -
Net income -459.65000M -123.12400M -50.65200M -51.36500M -56.49600M
Selling general administrative 81.21M 99.11M 31.58M 26.15M 19.66M
Selling and marketing expenses 99.11M 86.77M 33.71M 30.05M 23.46M
Gross profit 164.24M 141.00M 76.69M 58.82M 34.24M
Reconciled depreciation 46.38M 42.61M 8.21M 8.52M 9.39M
Ebit 135.90M -171.14100M -46.77700M -48.20400M -54.06700M
Ebitda 182.27M -128.66600M -38.71200M -39.79500M -44.67600M
Depreciation and amortization 46.38M 42.48M 8.06M 8.41M 9.39M
Non operating income net other -0.01500M -0.13300M -0.14700M - -
Operating income 135.90M -171.14100M -46.77700M -48.20400M -53.97700M
Other operating expenses 526.95M 481.16M 217.13M 180.71M 148.79M
Interest expense 0.26M 2.90M 3.72M 2.92M 2.37M
Tax provision -3.62400M -5.63900M 0.00400M 0.13M 0.06M
Interest income 0.26M - - - 2.37M
Net interest income 0.26M -2.90500M -3.72400M -2.92500M -2.37400M
Extraordinary items - - - - -
Non recurring 299.70M - - - -
Other items - - - - -
Income tax expense -3.62400M -5.63900M 0.00400M 0.13M 0.06M
Total revenue 363.14M 310.02M 170.36M 132.51M 94.81M
Total operating expenses 328.05M 312.14M 123.46M 107.03M 88.22M
Cost of revenue 198.91M 169.02M 93.67M 73.69M 60.57M
Total other income expense net -599.17000M 42.38M -3.87100M -3.03200M -0.09000M
Discontinued operations - - - - -
Net income from continuing ops -459.65000M -123.12400M -50.65200M -51.36500M -56.49600M
Net income applicable to common shares -459.65000M -123.12400M -50.65200M -51.36500M -56.49600M
Preferred stock and other adjustments - - - - -
Breakdown 2024-02-29 2023-02-28 2022-02-28 2021-02-28 2020-02-29
Type yearly yearly yearly yearly yearly
Date 2024-02-29 2023-02-28 2022-02-28 2021-02-28 2020-02-29
Total assets 788.15M 903.07M 1285.53M 475.51M 124.41M
Intangible assets 165.41M 203.20M 244.69M 0.60M 2.05M
Earning assets - - - - -
Other current assets 15.81M 14.15M 9.47M 5.96M 12.94M
Total liab 342.69M 429.28M 429.74M 84.66M 148.19M
Total stockholder equity 445.46M 473.79M 855.79M 390.85M -23.77300M
Deferred long term liab - - 4.56M 5.19M 3.88M
Other current liab 52.24M 51.09M 50.19M 40.79M 31.09M
Common stock 0.00800M 0.00700M 0.00700M 0.00600M 0.00400M
Capital stock 0.00800M 0.00700M 0.00700M 0.00600M 0.00400M
Retained earnings -1054.09900M -954.29400M -494.64400M -371.52000M -320.86800M
Other liab - - 4.83M 5.59M 5.92M
Good will 278.19M 278.19M 577.90M 4.01M 4.01M
Other assets 0.00000M - 8.88M 7.68M 4.62M
Cash 185.72M 321.08M 365.85M 433.88M 84.32M
Cash and equivalents - - - - -
Total current liabilities 107.85M 119.41M 111.75M 79.08M 69.96M
Current deferred revenue 34.77M 50.88M 47.14M 30.89M 33.59M
Net debt 55.93M -4.28700M -46.11200M -433.88400M -12.01100M
Short term debt 7.09M 7.28M 6.59M - -
Short long term debt 0.44M 0.60M 0.60M - -
Short long term debt total 241.65M 316.80M 319.74M - 72.31M
Other stockholder equity 1499.60M 1428.07M 1350.43M 762.36M 297.09M
Property plant equipment - 14.76M 11.80M 9.23M 13.62M
Total current assets 280.54M 365.95M 409.14M 453.98M 100.10M
Long term investments - - - - -
Net tangible assets - -7.60700M 33.21M 386.23M -262.86200M
Short term investments 51.31M - - - -
Net receivables 27.70M 26.70M 30.80M 11.84M 1.19M
Long term debt 208.48M 282.32M 280.67M - 72.31M
Inventory 0.00000M 4.02M 3.02M 2.30M 1.65M
Accounts payable 13.75M 10.15M 7.84M 7.39M 5.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.04700M - - -475.51000M -50.60800M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00700M 0.00600M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - -954.29400M -494.64400M -371.52000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 16.53M 11.44M 8.88M 7.68M 4.62M
Deferred long term asset charges - - - - -
Non current assets total 507.61M 537.12M 876.39M 21.53M 24.31M
Capital lease obligations 32.73M 34.47M 39.08M - -
Long term debt total - 282.32M 280.67M - -
Breakdown 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Type yearly yearly yearly yearly yearly
Date 2023-02-28 2022-02-28 2021-02-28 2020-02-29 2019-02-28
Investments -7.22800M -263.61300M -2.42300M -3.52100M -3.11800M
Change to liabilities 4.92M 9.57M 16.65M 8.12M 17.71M
Total cashflows from investing activities -7.22800M -263.61300M -2.42300M -3.52100M -3.11800M
Net borrowings - 279.13M -22.75300M 1.66M -2.10200M
Total cash from financing activities 3.16M 257.93M 428.38M 28.22M 48.83M
Change to operating activities -10.01300M -10.06900M 14.08M -12.84300M -1.18100M
Net income -459.65000M -123.12400M -50.65200M -51.36500M -56.49600M
Change in cash -44.77000M -68.03100M 400.73M -9.54600M 29.17M
Begin period cash flow 365.85M 433.88M 33.16M 42.70M 13.53M
End period cash flow 321.08M 365.85M 433.88M 33.16M 42.70M
Total cash from operating activities -40.70500M -62.35000M -25.23200M -34.24700M -16.54800M
Issuance of capital stock 0.00000M 0.00000M 439.41M 19.94M 49.93M
Depreciation 46.38M 42.61M 8.21M 8.52M 9.39M
Other cashflows from investing activities -5.12300M -261.09200M -0.43200M -0.05800M -0.05800M
Dividends paid - - - - -
Change to inventory - - 7.66M - -
Change to account receivables 4.11M -11.82900M -10.64800M -0.68300M 6.52M
Sale purchase of stock 4.99M 13.24M 451.14M - 50.94M
Other cashflows from financing activities 3.16M -189.28600M 62.89M -3.52100M 53.94M
Change to netincome 374.01M 29.20M 11.83M 13.02M 6.71M
Capital expenditures 7.23M 3.62M 2.37M 3.31M 3.12M
Change receivables - - - - -
Cash flows other operating -6.36300M -20.59800M -11.26700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -44.77000M -68.03100M 400.73M - -
Change in working capital -1.14200M -7.84300M 3.72M -5.40200M 23.84M
Stock based compensation 72.64M 72.94M 9.58M 6.00M 5.72M
Other non cash items 305.06M -40.79800M 3.91M 1.82M 0.42M
Free cash flow -47.93300M -65.96700M -27.59700M -37.56200M -19.66600M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACCD
Accolade Inc		 - -% - - - 0.66 0.70 0.68 -11.7804
GEHC
GE HealthCare Technologies Inc.		 -0.005 0.0067% 74.11 22.91 20.12 2.01 5.52 2.39 13.30
VEEV
Veeva Systems Inc Class A		 -0.16 0.07% 241.28 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 12.95 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 -0.04 0.61% 6.54 31.84 26.25 0.05 4.60 0.04 0.12

Reports Covered

Stock Research & News

View All

Profile

Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Accolade Inc

1201 Third Avenue, Seattle, WA, United States, 98101

Key Executives

Name Title Year Born
Mr. Rajeev Singh Chairman & CEO 1968
Mr. Robert Cavanaugh Pres 1969
Mr. Stephen H. Barnes CPA CFO & Treasurer 1972
Mr. Michael W. Hilton Chief Innovation Officer 1965
Mr. Todd Friedman Sr. VP of Investor Relations NA
Mr. Richard Eskew EVP, Gen. Counsel, CCO & Sec. NA
Ms. Carolina Lobo Chief Marketing Officer NA
Ms. Kristen Keating Weeks VP of Strategy, Corp. Devel. & Partnerships NA
Ms. Jennifer Hanson Exec. VP of People and Culture & Chief HR Officer NA
Mr. Todd Clardy Exec. VP & GM of Mid-Market Bus. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.